Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
An announcement from Qiagen ( (QGEN) ) is now available.
QIAGEN N.V. announced a synthetic share repurchase resulting in the consolidation of shares, where every 36 shares were consolidated into 35 shares. This transaction, which affects stakeholders including board member Metin Colpan, was part of a broader strategy approved in 2024 to streamline the company’s share structure.
More about Qiagen
QIAGEN N.V. operates within the life sciences industry, primarily focusing on providing sample and assay technologies for molecular diagnostics, applied testing, academic research, and pharmaceutical applications. The company is known for its innovative solutions that enable customers to gain valuable insights from biological samples.
YTD Price Performance: -0.02%
Average Trading Volume: 949,621
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $9.69B
For an in-depth examination of QGEN stock, go to TipRanks’ Stock Analysis page.
